Literature DB >> 17982493

Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.

M Remberger1, J Mattsson, Z Hassan, N Karlsson, K LeBlanc, B Omazic, M Okas, D Sairafi, O Ringdén.   

Abstract

We analysed factors associated with moderate to severe acute GVHD in 111 patients treated with fludarabin-based reduced intensity conditioning (RIC) and allogeneic haematopoietic stem cell transplantation (HSCT). Most patients had a haematological malignancy. Donors were 97 HLA-A, -B and -DRbeta1 identical unrelated and 14 HLA-A, -B or -DRbeta1 allele mismatched unrelated donors. In the univariate analysis, we found ten factors associated with acute GVHD. These were diagnosis (P=0.06), GVHD prophylaxis with combinations other than CsA+MTX (P=0.006), graft nucleated (P<0.001) and CD34 (P<0.001) cell-dose, bidirectional ABO mismatch (P=0.001), conditioning (P=0.002), hospital vs home-care (P=0.06), ATG dose (P<0.001), donor herpes virus serology (P=0.07) and an immunized female donor to male recipient (P=0.05). In the multivariate analysis, three factors remained significant: a high CD34 cell dose (P<0.001), low dose (4 mg/kg) ATG (P<0.001), and an immunized female donor to male recipient (P<0.01). Patients receiving a CD34 cell dose > or =17.0 x 10(6) per kg had a higher incidence of GVHD, 53.7%, compared to 22.3% in patients receiving a lower dose (P=0.002). In patients without any of these risk factors (n=70), the incidence of acute GVHD was 14.1%, while it was 38.0 and 85.0% in patients with one (n=29) or two (n=10) risk factors (P<0.001). We concluded that risk factors for acute GVHD using RIC are similar as using myeloablative conditioning.

Entities:  

Mesh:

Year:  2007        PMID: 17982493     DOI: 10.1038/sj.bmt.1705913

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  13 in total

Review 1.  Clinical impact of H-Y alloimmunity.

Authors:  Rakesh Popli; Bita Sahaf; Hideki Nakasone; Joyce Yeuk Yu Lee; David B Miklos
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 2.  A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.

Authors:  Mohammad Vaezi; Maryam Souri; Seyed Amin Setarehdan; Amir Ali Hamidieh; Mohammad Reza Fazlollahi; Zahra Pourpak; Mohsen Badalzadeh; Shaghayegh Tajik; Seyed Alireza Mahdaviani; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

Review 3.  Advances in predicting acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; John E Levine
Journal:  Br J Haematol       Date:  2012-12-04       Impact factor: 6.998

Review 4.  Prophylaxis of acute GVHD: manipulate the graft or the environment?

Authors:  A John Barrett; Katarina Le Blanc
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

5.  Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Johan Törlén; Olle Ringdén; Jennifer Le Rademacher; Minoo Batiwalla; Junfang Chen; Tom Erkers; Vincent Ho; Partow Kebriaei; Carolyn Keever-Taylor; Tamila Kindwall-Keller; Hillard M Lazarus; Mary J Laughlin; Michael Lill; Tracey O'Brien; Miguel-Angel Perales; Vanderson Rocha; Bipin N Savani; David Szwajcer; David Valcarcel; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

6.  Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.

Authors:  Muna Qayed; Tao Wang; Michael T Hemmer; Stephen Spellman; Mukta Arora; Daniel Couriel; Amin Alousi; Joseph Pidala; Hisham Abdel-Azim; Mahmoud Aljurf; Mouhab Ayas; Menachem Bitan; Mitchell Cairo; Sung Won Choi; Christopher Dandoy; David Delgado; Robert Peter Gale; Gregory Hale; Haydar Frangoul; Rammurti T Kamble; Mohamed Kharfan-Dabaja; Leslie Lehman; John Levine; Margaret MacMillan; David I Marks; Taiga Nishihori; Richard F Olsson; Peiman Hematti; Olov Ringden; Ayman Saad; Prakash Satwani; Bipin N Savani; Kirk R Schultz; Sachiko Seo; Shalini Shenoy; Edmund K Waller; Lolie Yu; Mary M Horowitz; John Horan
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-16       Impact factor: 5.742

7.  Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.

Authors:  Robert M Dean; Terry Fry; Crystal Mackall; Seth M Steinberg; Fran Hakim; Daniel Fowler; Jeanne Odom; Jason Foley; Ronald Gress; Michael R Bishop
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

8.  Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.

Authors:  Emilia Jaskula; Dorota Dlubek; Agnieszka Tarnowska; Janusz Lange; Monika Mordak-Domagala; Krzysztof Suchnicki; Mariola Sedzimirska; Agata Borowik; Sylwia Mizia; Andrzej Lange
Journal:  Viruses       Date:  2015-03-23       Impact factor: 5.048

9.  An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution.

Authors:  Zheng-Ping Yu; Jia-Hua Ding; Bao-An Chen; Yu-Feng Li; Bang-He Ding; Jun Qian
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Different subsets of haematopoietic cells and immune cells in bone marrow between young and older donors.

Authors:  W-L Yao; Q Wen; H-Y Zhao; S-Q Tang; Y-Y Zhang; Y Wang; L-P Xu; X-H Zhang; X-J Huang; Y Kong
Journal:  Clin Exp Immunol       Date:  2020-10-21       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.